{"nctId":"NCT02104947","briefTitle":"Reversal of Dabigatran Anticoagulant Effect With Idarucizumab","startDateStruct":{"date":"2014-05-06","type":"ACTUAL"},"conditions":["Hemorrhage"],"count":503,"armGroups":[{"label":"idarucizumab","type":"EXPERIMENTAL","interventionNames":["Drug: idarucizumab"]}],"interventions":[{"name":"idarucizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Group A (Bleeding patients)\n\n  * Overt bleeding judged by the physician to require a reversal agent\n  * Currently taking dabigatran etexilate\n  * At least 18 years of age\n  * Written informed consent\n* Group B (Patients who are taking dabigatran who may not be bleeding, but do require an emergency surgery or procedure for a condition other than bleeding\n\n  * Condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours.\n  * Current treatment with dabigatran\n  * At least 18 years of age\n  * Written Informed consent.\n\nExclusion criteria:\n\n* Group A (Bleeding Patients)\n\n  * Patients with minor bleeds (epistaxis, hematuria) who can be managed with standard supportive care.\n  * Patients with no clinical signs of bleeding\n  * Contraindications to study medication including known hypersensitivity to the drug or its excipients.\n* Group B (Patients who require emergency surgery or procedure)\n\n  * A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.\n  * Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT","description":"Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time (dTT) or ecarin clotting time (ECT), at any time point from the end of the first infusion up to 4 hours after the last infusion.\n\nReversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).\n\nReversal is calculated as 100\\* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is \\> 100, it was set to 100.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Reversal of aPTT and TT From Central Laboratory","description":"Reversal of anticoagulation as measured by Activated Partial Thromboplastin Time (aPTT) and Thrombin time (TT), at any time point since the end of first infusion up to 4 hours after the completion of the last infusion. Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).\n\nReversal is calculated as 100\\* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is \\> 100, it was set to 100.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Reversal","description":"Duration of reversal, defined as the time period a patient remained completely reversed based on dTT or ECT, up to 24 hours or re-starting the treatment of dabigatran.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"10.0"},{"groupId":"OG001","value":"12.8","spread":"9.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":"6.7"},{"groupId":"OG001","value":"18.8","spread":"7.6"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Major/Life-threatening/Fatal Bleeding (for Group B Only) Intraoperatively","description":"Occurrence of major/life-threatening/fatal bleeding (for group B only) intraoperatively and up to 24 hours post-surgery were classified according to major or life-threatening bleeding (ISTH \\[International Society for Thrombosis and Hemostasis\\] definition). 95% Confidence Interval (CI) is from Clopper-Pearson method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cessation of Bleeding (for Group A Only)","description":"Time to cessation of bleeding (for Group A only) since first infusion up to 24 hours after the completion of second infusion; bleeding status was to be categorized before and at several time points after treatment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.73","spread":null},{"groupId":"OG001","value":"2.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Cmin,1 of Unbound Sum (Free) Dabigatran","description":"Cmin,1 (Minimum concentrations at any time point since the end of first vial of idarucizumab up to 4 hours after the completion of second vial) of unbound sum (free) dabigatran, provided that two vials given not more than 15 min apart in group A and B.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"61.2"}]}]}]},{"type":"SECONDARY","title":"Reversal of Anticoagulation as Measured by Diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) After the First Vial of Idarucizumab and Before the Start of Second Vial","description":"Reversal of anticoagulation as measured by diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first vial of idarucizumab and before the start of second vial.\n\nReversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients). Reversal is calculated as 100\\*(pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is \\> 100, it was set to 100.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":160,"n":301},"commonTop":["Constipation","Urinary tract infection","Nausea","Headache","Diarrhoea"]}}}